These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24843563)

  • 1. Ezetimibe improves glucose metabolism by ameliorating hepatic function in Japanese patients with type 2 diabetes.
    Ichimori S; Shimoda S; Goto R; Matsuo Y; Maeda T; Furukawa N; Kawashima J; Kodama S; Sekigami T; Isami S; Nishida K; Araki E
    J Diabetes Investig; 2012 Mar; 3(2):179-84. PubMed ID: 24843563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ezetimibe ameliorates atherosclerotic and inflammatory markers, atherogenic lipid profiles, insulin sensitivity, and liver dysfunction in Japanese patients with hypercholesterolemia.
    Tamaki N; Ueno H; Morinaga Y; Shiiya T; Nakazato M
    J Atheroscler Thromb; 2012; 19(6):532-8. PubMed ID: 22353686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial.
    Takeshita Y; Takamura T; Honda M; Kita Y; Zen Y; Kato K; Misu H; Ota T; Nakamura M; Yamada K; Sunagozaka H; Arai K; Yamashita T; Mizukoshi E; Kaneko S
    Diabetologia; 2014 May; 57(5):878-90. PubMed ID: 24407920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease.
    Abel T; Fehér J; Dinya E; Eldin MG; Kovács A
    Med Sci Monit; 2009 Dec; 15(12):MS6-11. PubMed ID: 19946244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled study of the effect of ezetimibe on glucose metabolism in subjects with type 2 diabetes mellitus and hypercholesterolemia.
    Saito I; Azuma K; Kakikawa T; Oshima N; Hanson ME; Tershakovec AM
    Lipids Health Dis; 2015 May; 14():40. PubMed ID: 25929253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials.
    Gallo S; Calle RA; Terra SG; Pong A; Tarasenko L; Raji A
    Diabetes Ther; 2020 Aug; 11(8):1849-1860. PubMed ID: 32648108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes.
    Vozarova B; Stefan N; Lindsay RS; Saremi A; Pratley RE; Bogardus C; Tataranni PA
    Diabetes; 2002 Jun; 51(6):1889-95. PubMed ID: 12031978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Traditional Chinese Medicine formula Dai-Zong-Fang alleviating hepatic steatosis in
    Zhang LW; Zhu LL; Zhu XY; Fu SQ; Liu XM
    Front Pharmacol; 2024; 15():1337057. PubMed ID: 38327989
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study.
    Itani T; Ishihara T
    Obes Sci Pract; 2018 Oct; 4(5):477-482. PubMed ID: 30338118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy and safety of ezetimibe/simvastatin combination therapy in patients with type 2 diabetes and nonalcoholic fatty liver disease].
    Abel T; Fehér J; Dinya E; Gamal Eldin M; Kovács A
    Orv Hetil; 2009 May; 150(21):989-93. PubMed ID: 19443308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ezetimibe improves hepatic steatosis in relation to autophagy in obese and diabetic rats.
    Chang E; Kim L; Park SE; Rhee EJ; Lee WY; Oh KW; Park SW; Park CY
    World J Gastroenterol; 2015 Jul; 21(25):7754-63. PubMed ID: 26167075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet.
    Muraoka T; Aoki K; Iwasaki T; Shinoda K; Nakamura A; Aburatani H; Mori S; Tokuyama K; Kubota N; Kadowaki T; Terauchi Y
    Metabolism; 2011 May; 60(5):617-28. PubMed ID: 20673929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid and liver abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes.
    Calanna S; Scicali R; Di Pino A; Knop FK; Piro S; Rabuazzo AM; Purrello F
    Nutr Metab Cardiovasc Dis; 2014 Jun; 24(6):670-6. PubMed ID: 24656139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relations of hepatic steatosis with liver functions, inflammations, glucolipid metabolism in chronic hepatitis B patients.
    Chen XL; Han YD; Wang H
    Eur Rev Med Pharmacol Sci; 2018 Sep; 22(17):5640-5646. PubMed ID: 30229840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations of White Blood Cell Count,Alanine Aminotransferase,and Aspartate Aminotransferase in the First Trimester withGestational Diabetes Mellitus.
    Zhao LL; Li W; Ping F; Ma LK; Nie M
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Jun; 38(3):283-7. PubMed ID: 27469912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of MK615 for the treatment of patients with liver disorders.
    Hokari A; Ishikawa T; Tajiri H; Matsuda T; Ishii O; Matsumoto N; Okuse C; Takahashi H; Kurihara T; Kawahara K; Maruyama I; Zeniya M
    World J Gastroenterol; 2012 Aug; 18(31):4118-26. PubMed ID: 22919243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Niemann-Pick C1 like 1 (NPC1L1) inhibitor ezetimibe improves metabolic disease via decreased liver X receptor (LXR) activity in liver of obese male mice.
    Sugizaki T; Watanabe M; Horai Y; Kaneko-Iwasaki N; Arita E; Miyazaki T; Morimoto K; Honda A; Irie J; Itoh H
    Endocrinology; 2014 Aug; 155(8):2810-9. PubMed ID: 24773344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
    Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
    Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial.
    Obońska K; Kasprzak M; Sikora J; Obońska E; Racki K; Goździkiewicz N; Krintus M; Kubica J
    Trials; 2017 Jul; 18(1):316. PubMed ID: 28697767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study.
    Hanley AJ; Williams K; Festa A; Wagenknecht LE; D'Agostino RB; Kempf J; Zinman B; Haffner SM;
    Diabetes; 2004 Oct; 53(10):2623-32. PubMed ID: 15448093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.